Prognostic Role of c-Met Overexpression in High Grade Glioma: a Meta-analysis

ObjectivesThis study aims to assess the relationship between the expression of c-Met and the prognosis of high grade glioma patients.\n\nMethodThe MET proto-oncogene encoded c-Met protein. The gene expression data of 325 patients were downloaded from CGGA. The Oncomine database analysis and the prognosis analysis were conducted. Besides, meta-analysis was also performed to confirm the conclusion.\n\nResultOncomine database was identified and analyzed and results showed that the MET copy number was obviously higher in glioblastoma than normal tissue consistently (p<0.001). The prognostic analysis of 325 high grade glioma samples showed that high c-Met expression patients had poor overall survival (OS) and progression free survival (PFS) than the low c-Met expression patients dramatically (HR, 2.223; 95% CI: 1.662 to 2.974; P<0.0001 and HR, 2.089; 95% CI: 1.578 to 2.770; P<0.0001). 6 studies involving 503 patients were included in the meta-analysis. The pooled results indicated that the high expression of c-Met was not significantly associated with OS (HR =1.01, 95% CI:0.93-1.09), but strongly connected with shorter PFS (HR =1.92, 95% CI:1.42-2.58, p<0.01).\n\nConclusionc-Met overexpression has correlation with poor prognosis of high grade glioma patients.